MagVigen™ Plasma DNA Capture Kit Cat# K61003
| Name | Application | Cat# | Price | Add to cart |
| MagVigen™ – Plasma DNA Capture Kit | For DNA capture from plasma samples. Proteinase K and buffer included. Product Sheet |
K61003- |
MagVigen™ Plasma DNA Capture Kit (Cat# K61003) is specially designed to capture cell free DNA (cfDNA) from Plasma or Serum with no need of column or centrifugation.
The Magnetic Workflow
Figure 1. The magnetic workflow.
MagVigen™ cfDNA Extraction workflow can be scaled up linearly from 100 µl to 10 ml of plasma input samples. cfDNA isolated with MagVigen™ cfDNA kit presents high quality for downstream PCR or sequencing assays. The yield and quality of extracted cfDNA can be significantly better than other methods on market.
And MagVigen™ allows simple and efficient DNA extraction ideal for automation.
Figure 2. NVIGEN cfDNA kit presents higher yield and higher quality for PCR and NGS library.
Figure 3. Clean bioanalyzer profiles showing higher yield and higher quality NGS library from cfDNA extracted with NVIGEN Kit vs. Q-ccf Kit.
Figure 4. Higher yield with 4 ml plasma input.
Figure 5. Efficiency of DNA recovery. Bioanalyzer files of original ladder DNA (red line) and recovered spiked-in ladder DNA after extraction (blue line).
Figure 6. cfDNA extraction yield and size from 1.5 ml plasma samples with (blue) and without (red) spiking in DNA. Calculated yield of spiking in DNA by subtraction of endogenous cfDNA from total DNA were 80% using picogreen assay and 91% with bioanalyzer quantification.
Figure 7. Higher capture rate for smaller sizes of cfDNA is possible with NVIGEN MagVigen-cfDNA extraction kit.
Figure 8. The yield of cfDNA increases in proporation to the volume of plasma input. Captured cfDNA was quantified by pico-green analysis.
Figure 9. cfDNA extraction yield was quantified by pico-green analysis following DNA isolation with the MagVigen™ Plasma DNA Capture Kit and kit C.
Figure 10. Beta-globin level and GAPDH levels were estimated by PCR analysis.
Figure 11. NIPT Sequencing library constructed with NVIGEN cfDNA and DNA sizing kits in genomic diagnostic company using real clinical samples.
Figure 12. Much better differentiation between patient plasma and normal plasma was achieved using MagVigen cfDNA extraction followed by sequence specific target capture with MagVigen-Streptavidin nanobeads vs. MyOne-Streptavidin beads. The qPCR Ct differences between patient and normal plasma samples were over 9 when using MagVigen-Streptavidin Nanobeads (Cat# K61002) and less than 2 when using MyOne-Streptavidin beads, corresponding to over 100x better differentiation power when referring to ctDNA copy numbers of the original plasma samples of 2^9 vs. 2^2.
